San Diego molecular information firm AltheaDx Inc. has raised $27 million in a Series D funding, the company announced.
AltheaDx, which provides diagnostics to help doctors prescribe personalized treatments for patients, said it will use the funding to expand its sales force and scale up marketing efforts for its IDgenetix testing portfolio.
"This financing is an important milestone in the continued commercialization of our IDgenetix offering and the growth of AltheaDx," said Jorge Garces, president and chief executive officer. "We now have strong clinical evidence further demonstrating the clinical utility of our testing in improving patient outcomes with clear health economic benefits and we will continue to work with payers to secure long-term reimbursement."
The company is also considering international expansion, it said.
Last year, AltheaDx raised $6 million in debt financing, according to forms filed with the Securities and Exchange Commission.
In 2015, the firm raised $30 million in a Series C financing. WuXi Healthcare Ventures led the deal, which was joined by WuXi PharmaTech, Ally Bridge Group, and ALMA Life Sciences, according to the company.